Terazosin
Product Images NDC 10544-289

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 10544-289). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Figure1)

Figure 1 consists of two line graphs from Study 1 comparing Terazosin and Placebo groups. The left graph shows mean change in total symptom score from baseline over 3 months, with Terazosin group showing a larger decrease. The right graph depicts mean increase in peak flow rate (mL/sec) from baseline over 3 months, with Terazosin group showing a greater increase. Both graphs include error bars and sample sizes (N).*

FDA Label Image

Formula 2 (Figure2)

A line graph depicting the mean change in total symptom score from baseline over 30 months in a long-term, open-label, non-placebo controlled study with 494 participants. The vertical axis represents mean change from baseline, showing improvement, and the horizontal axis is time in months, from 0 to 30 months. The graph highlights significant changes from baseline (p ≤ 0.05) at multiple points during the study.*

FDA Label Image

Figure 3 (Figure3)

A line graph titled 'Mean Change in Peak Flow Rate from Baseline' from a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis represents months (0 to 30), and the y-axis shows the mean change from baseline in mL/sec, ranging from 0.0 to 4.5. Data points indicate an increase in peak flow rate over time with statistical significance markers at multiple time points, denoting p ≤ 0.05 versus baseline.*

FDA Label Image

Label (Label Terazosin Caps 10mg Bpi(10544 289 30) Apotex(60505 0118 0) Rev2)

Terazosin Capsules USP 10mg label by Blenheim Pharmacal, Inc. The label states the product contains 30 capsules with NDC 10544-289-30 and manufacturer code 60505-0118-0. It includes storage instructions to keep at controlled room temperature and protect from light and moisture. The label notes the product is Rx only and urges users to see the package insert. It also shows a barcode and repeated smaller print versions on the right side with matching information.*

FDA Label Image

Formula (Formula)

Chemical structure of Terazosin, showing its molecular arrangement including a quinazoline core, piperazine ring, and hydrophilic groups, commonly represented with hydrochloride and dihydrate components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.